new glp-1 drug Retatrutide for weight loss: Study shows 30% body weight loss GLP-1 use tripled among non-diabetics,

Yes, multiple studies confirm reduced CRP and IL-6 levels

The initial dosing regimen of semaglutide subcutaneous injection is 0.25 mg weekly, with the dose increased up to 2 mg for Ozempic and 2.4 mg for Wegovy , respectively, usually after one month at the previous dose

Treatment with GLP-1RAs leads to rapid reduction in blood pressure, which, according to a meta-analysis (266), could substantially lower the risk of cardiovascular disease and mortality

The short-acting preparation of GLP-1RA mainly reduces postprandial blood glucose by delaying gastric emptying and increasing insulin secretion (59)

Additionally, PPAR activation inhibits transcription factors like NF- B, preventing atherosclerosis by suppressing the expression of cytokines and adhesion molecules in endothelial cells